While some groups have suggested that canagliflozin's anticancer properties are linked to the inhibition of glucose transport via SGLT2 [21, 22, 23], this transporter is functionally present only in certain cancers [23], and emerging evidence indicates that additional mechanisms are at play [24, 25]. Here, SLC5A2 is linked to cancer.